These results indicate that the IRGM/YBX1 axis suppresses CD8+ CTL infiltration and function via PD-L1 regulation, promoting HCC progression, and suggest a potential combination strategy with immune checkpoint blockade (ICB) (17). The gene discussed is IRGM; the disease is hepatocellular carcinoma.